End-of-day quote
Korea S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
15,340
KRW
|
+0.39%
|
|
+6.45%
|
+23.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
2,033,947
|
3,213,545
|
1,638,629
|
1,055,253
|
493,381
|
610,852
|
-
|
Enterprise Value (EV)
1 |
2,033,996
|
3,213,467
|
1,638,537
|
1,055,253
|
493,381
|
610,852
|
610,852
|
P/E ratio
|
19.2
x
|
121
x
|
-438
x
|
-39.6
x
|
-7.55
x
|
-14.6
x
|
-120
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.97
x
|
9.49
x
|
7.99
x
|
-
|
4.93
x
|
4.16
x
|
2.36
x
|
EV / Revenue
|
2.97
x
|
9.49
x
|
7.99
x
|
-
|
4.93
x
|
4.16
x
|
2.36
x
|
EV / EBITDA
|
13,969,708,737
x
|
72,938,211,141
x
|
-118,388,749,395
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-94,477,474
x
|
33,157,656
x
|
43,060,197
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
9.12
x
|
13.2
x
|
6.54
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
39,803
|
39,821
|
39,821
|
39,821
|
39,821
|
39,821
|
-
|
Reference price
2 |
51,100
|
80,700
|
41,150
|
26,500
|
12,390
|
15,340
|
15,340
|
Announcement Date
|
2/13/20
|
2/22/21
|
2/25/22
|
3/23/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
684.9
|
338.5
|
205.2
|
-
|
100.1
|
147
|
259
|
EBITDA
|
145.6
|
44.06
|
-13.84
|
-
|
-
|
-
|
-
|
EBIT
1 |
137.9
|
32.66
|
-27.88
|
-
|
-62.86
|
-41.9
|
-5.1
|
Operating Margin
|
20.14%
|
9.65%
|
-13.59%
|
-
|
-62.82%
|
-28.5%
|
-1.97%
|
Earnings before Tax (EBT)
|
132.7
|
24.2
|
-4.797
|
-
|
-53.05
|
-
|
-
|
Net income
1 |
108.8
|
26.64
|
-4.124
|
-26.69
|
-65.29
|
-41.9
|
-5.1
|
Net margin
|
15.89%
|
7.87%
|
-2.01%
|
-
|
-65.24%
|
-28.5%
|
-1.97%
|
EPS
2 |
2,655
|
669.0
|
-94.00
|
-670.0
|
-1,640
|
-1,051
|
-128.0
|
Free Cash Flow
|
-21,528
|
96,917
|
38,054
|
-
|
-
|
-
|
-
|
FCF margin
|
-3,143.45%
|
28,631.69%
|
18,548.73%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
219,973.97%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
363,826.99%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/22/21
|
2/25/22
|
3/23/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
36.21
|
44.04
|
40.67
|
39.92
|
53.51
|
37.43
|
18.7
|
18.36
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.243
|
-11.03
|
-10.68
|
-12.72
|
-8.479
|
-13.53
|
-22.27
|
-10.84
|
Operating Margin
|
-25.52%
|
-25.05%
|
-26.26%
|
-31.88%
|
-15.85%
|
-36.14%
|
-119.09%
|
-59.05%
|
Earnings before Tax (EBT)
|
-3.381
|
-9.749
|
-
|
-10.18
|
-1.606
|
-10.89
|
-
|
-
|
Net income
|
-3.552
|
-7.597
|
-
|
-5.361
|
-1.336
|
-9.728
|
-
|
-
|
Net margin
|
-9.81%
|
-17.25%
|
-
|
-13.43%
|
-2.5%
|
-25.99%
|
-
|
-
|
EPS
|
-89.00
|
-191.0
|
-245.0
|
-135.0
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
2/25/22
|
5/13/22
|
8/16/22
|
11/14/22
|
5/15/23
|
8/11/23
|
11/14/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
48.8
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
77.8
|
92
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.3354
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-21,528
|
96,917
|
38,054
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
67.8%
|
8.97%
|
-1.67%
|
-
|
-
|
-30.5%
|
-
|
ROA (Net income/ Total Assets)
|
29.3%
|
4.98%
|
-0.98%
|
-
|
-
|
-
|
-
|
Assets
1 |
371.3
|
534.5
|
418.8
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5,605
|
6,127
|
6,291
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-94.50
|
3,021
|
-
|
-
|
-
|
-
|
-
|
Capex
|
17.9
|
23.4
|
9.53
|
-
|
-
|
-
|
-
|
Capex / Sales
|
2.61%
|
6.9%
|
4.64%
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/22/21
|
2/25/22
|
3/23/23
|
3/21/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +23.81% | 442M | | -3.53% | 2.24B | | -13.94% | 854M | | +0.07% | 758M | | -20.15% | 714M | | +17.68% | 484M | | +1.37% | 432M | | -13.85% | 192M | | -32.71% | 187M | | +6.93% | 175M |
Broadcasting Equipment
|